Terence H. Rabbitts

Institute of Cancer Research — Canada

Medicine · Health Sciences

91h-index28.1kcitations373works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(104), T-cell and Retrovirus Studies(54), Immune Cell Function and Interaction(48), CAR-T cell therapy research(43), Chronic Lymphocytic Leukemia Research(39)

Publications373 total

Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis
eLife·2025Open Access
Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis
2025Open Access
Author response: Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis
2025Open Access
Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis
eLife·2025Open Access
Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis
2025Open Access
Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis
2024Open Access
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation
Cancers·2023· 5 citedOpen Access
Supplementary Figure 1 from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Supplementary Methods from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Data from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Supplementary Figure 1 from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Data from Sequential Gene Targeting to Make Chimeric Tumor Models with <i>De Novo</i> Chromosomal Abnormalities
2023Open Access
Supplementary Figures 1 - 5 from Sequential Gene Targeting to Make Chimeric Tumor Models with <i>De Novo</i> Chromosomal Abnormalities
2023Open Access
Supplementary Methods from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Data from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Supplementary Figure 2 from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Data from Sequential Gene Targeting to Make Chimeric Tumor Models with <i>De Novo</i> Chromosomal Abnormalities
2023Open Access
Supplementary Figures 1 - 5 from Sequential Gene Targeting to Make Chimeric Tumor Models with <i>De Novo</i> Chromosomal Abnormalities
2023Open Access
Supplementary Figure 3 from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
Supplementary Figure 2 from Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia
2023Open Access
page 1 of 19Next →

Frequent Co-authors

A. Förster(18), Richard Baer(8), Alan J. Warren(6), Marie‐Paule Lefranc(6), Isabelle Lavenir(5), John G. Flanagan(4), Thomas Boehm(4), Richard Pannell(4), Matthew P. McCormack(3), Teresa Larson(3), M.A. Stinson(3), Yoshihiro Yamada(3), Pamela Hamlyn(3), David L. Bentley(3), H Osada(3), Jean Soulier(2), William H Colledge(2), Mark Carlton(2), Martin Evans(2), Andrew J.H. Smith(2)